Published in Lancet on November 02, 2013
Research into a functional cure for HIV in neonates: the need for ethical foresight. Lancet Infect Dis (2014) 1.16
What motivates participation in HIV cure trials? A call for real-time assessment to improve informed consent. J Virus Erad (2015) 0.96
The ethics of HIV "cure" research: what can we learn from consent forms? AIDS Res Hum Retroviruses (2015) 0.89
Practical considerations in gene therapy for HIV cure. Curr HIV/AIDS Rep (2014) 0.88
The potential of radioimmunotherapy as a new hope for HIV patients. Expert Rev Clin Immunol (2014) 0.81
In vivo platforms for analysis of HIV persistence and eradication. J Clin Invest (2016) 0.80
The benefit/risk ratio challenge in clinical research, and the case of HIV cure: an introduction. J Med Ethics (2016) 0.78
When to start paediatric testing of the adult HIV cure research agenda? J Med Ethics (2016) 0.78
Contractualist reasoning, HIV cure clinical trials, and the moral (ir)relevance of the risk/benefit ratio. J Med Ethics (2016) 0.77
Recent developments in clinical trial designs for HIV vaccine research. Hum Vaccin Immunother (2015) 0.77
In Vivo Models of Human Immunodeficiency Virus Persistence and Cure Strategies. J Infect Dis (2017) 0.75
Synergies, tensions and challenges in HIV prevention, treatment and cure research: exploratory conversations with HIV experts in South Africa. BMC Med Ethics (2016) 0.75
'Well, It's the Risk of the Unknown… Right?': A Qualitative Study of Perceived Risks and Benefits of HIV Cure Research in the United States. PLoS One (2017) 0.75
Interrupting antiretroviral treatment in HIV cure research: scientific and ethical considerations. J Virus Erad (2017) 0.75
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One (2009) 8.37
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med (2004) 6.87
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med (2003) 5.79
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis (2008) 5.20
Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis (2008) 5.14
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis (2003) 4.51
HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS (2007) 3.94
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis (2007) 3.75
Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med (2008) 3.66
Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med (2009) 3.52
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med (2014) 3.48
Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis (2005) 3.47
Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS One (2009) 3.40
Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med (2014) 3.24
Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA (2006) 3.23
Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA (2011) 3.08
Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med (2006) 3.06
HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis (2007) 3.05
Update of the Drug Resistance Mutations in HIV-1. Top HIV Med (2008) 2.91
Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med (2010) 2.91
Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med (2007) 2.79
Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J Clin Microbiol (2006) 2.45
Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis (2010) 2.45
Accuracy of the TRUGENE HIV-1 genotyping kit. J Clin Microbiol (2003) 2.32
Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS (2011) 2.22
Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis (2013) 2.17
Consequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group protocol 370. Antivir Ther (2002) 2.07
Xenotropic murine leukemia virus-related virus prevalence in patients with chronic fatigue syndrome or chronic immunomodulatory conditions. J Infect Dis (2010) 2.05
Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med (2005) 2.04
Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS (2002) 2.02
Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J Virol (2004) 1.91
Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial. J Acquir Immune Defic Syndr (2007) 1.90
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr (2005) 1.87
In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J Virol (2008) 1.84
Update of the Drug Resistance Mutations in HIV-1: 2005. Top HIV Med (2005) 1.83
In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J Virol (2005) 1.80
Outcomes after virologic failure of first-line ART in South Africa. AIDS (2010) 1.74
Drug resistance mutations in HIV-1. Top HIV Med (2003) 1.72
Instantaneous inhibitory potential is similar to inhibitory quotient at predicting HIV-1 response to antiretroviral therapy. Clin Infect Dis (2010) 1.72
Low-level detection and quantitation of cellular HIV-1 DNA and 2-LTR circles using droplet digital PCR. J Virol Methods (2012) 1.65
Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095. J Acquir Immune Defic Syndr (2007) 1.64
Update of the drug resistance mutations in HIV-1: 2004. Top HIV Med (2004) 1.62
Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen. J Infect Dis (2006) 1.62
Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211. J Infect Dis (2009) 1.61
High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. AIDS (2012) 1.60
Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095. Clin Infect Dis (2010) 1.53
Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistance. J Acquir Immune Defic Syndr (2005) 1.52
Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure. AIDS (2012) 1.52
Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J Acquir Immune Defic Syndr (2006) 1.49
Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals. J Acquir Immune Defic Syndr (2004) 1.48
Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Clin Infect Dis (2005) 1.47
Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy. J Infect Dis (2011) 1.45
In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine. J Virol (2008) 1.45
Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations. J Virol Methods (2007) 1.43
A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128. HIV Clin Trials (2003) 1.42
A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors. Curr Opin HIV AIDS (2009) 1.41
Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother (2008) 1.39
Drug resistance mutations in HIV-1. Top HIV Med (2004) 1.37
Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure. PLoS Pathog (2011) 1.32
Enumeration of CD4+ T-cells using a portable microchip count platform in Tanzanian HIV-infected patients. PLoS One (2011) 1.32
Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1. J Virol (2006) 1.32
Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa. PLoS One (2012) 1.31
Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness. J Acquir Immune Defic Syndr (2010) 1.30
Quantum dot-based HIV capture and imaging in a microfluidic channel. Biosens Bioelectron (2009) 1.27
Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248. J Infect Dis (2013) 1.26
Rapid automated cell quantification on HIV microfluidic devices. Lab Chip (2009) 1.25
Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen. J Infect Dis (2005) 1.25
The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS (2016) 1.25
Chemokine antagonists as therapeutics: focus on HIV-1. Annu Rev Med (2007) 1.24
AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein. J Infect Dis (2010) 1.24
Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095). J Acquir Immune Defic Syndr (2007) 1.20
Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1. J Virol (2011) 1.19
The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations. Antimicrob Agents Chemother (2005) 1.18
Efficient on-chip isolation of HIV subtypes. Lab Chip (2012) 1.17
A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115. Antivir Ther (2007) 1.17
Monitoring HIV treatment in developing countries. BMJ (2006) 1.13
Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia. Antimicrob Agents Chemother (2012) 1.13
The impact of the President's Emergency Plan for AIDS Relief (PEPfAR) beyond HIV and why it remains essential. Clin Infect Dis (2010) 1.12
Increased risk of virologic rebound in patients on antiviral therapy with a detectable HIV load <48 copies/mL. PLoS One (2012) 1.10
Clinical implications of HIV-1 minority variants. Clin Infect Dis (2013) 1.09
Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary. J Infect Dis (2007) 1.07
Acute on-chip HIV detection through label-free electrical sensing of viral nano-lysate. Small (2013) 1.07
HIV-1 entry inhibitors: recent development and clinical use. Curr Opin Virol (2013) 1.07
Nanoplasmonic quantitative detection of intact viruses from unprocessed whole blood. ACS Nano (2013) 1.07
The design and validation of a novel phenotypic assay to determine HIV-1 coreceptor usage of clinical isolates. J Virol Methods (2010) 1.06
HIV-1-infected antiretroviral-treated patients with prolonged partial viral suppression: clinical, virologic, and immunologic course. J Acquir Immune Defic Syndr (2003) 1.05
Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. Nanomedicine (Lond) (2010) 1.05
Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia. AIDS (2011) 1.05
Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence. J Pharmacokinet Pharmacodyn (2006) 1.05
Emerging technologies for point-of-care management of HIV infection. Annu Rev Med (2014) 1.05
Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients. J Acquir Immune Defic Syndr (2010) 1.04
Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals. AIDS Res Hum Retroviruses (2010) 1.04
Design issues in initial HIV-treatment trials: focus on ACTG A5095. Antivir Ther (2006) 1.04
Tropism testing in the clinical management of HIV-1 infection. Curr Opin HIV AIDS (2009) 1.03
Continued evolution in gp41 after interruption of enfuvirtide in subjects with advanced HIV type 1 disease. AIDS Res Hum Retroviruses (2006) 0.99
Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure. J Infect Dis (2012) 0.97
Simple filter microchip for rapid separation of plasma and viruses from whole blood. Int J Nanomedicine (2012) 0.97
Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211. Clin Infect Dis (2009) 0.96
Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate. J Acquir Immune Defic Syndr (2010) 0.96